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Background: Allergen immunotherapy (SIT) is the only treatment for allergic disease capable of modifying disease
long term. To reduce the risk of anaphylaxis from SIT, allergen-extracts have been modified by polymerisation with
glutaraldehyde to reduce IgE binding. It is suggested that these allergoid extracts also have reduced T cell activity,
which could compromise clinical efficacy. Effective SIT is thought to act through regulatory T cells (Tregs) rather
than activation of effector T cells. There is no published data on the activity of modified extracts on Tregs.
Results: We compared the capacity of modified (depigmented-polymerised) versus unmodified (native) allergen
extracts of grass pollen and house dust mite to stimulate proliferation/cytokine production and to modulate
Treg/effector T cell frequency in cultures of peripheral blood mononuclear cells (PBMC), from volunteers
sensitised to both allergens in vitro. Depigmented-polymerised allergen extracts stimulated less proliferation of
PBMC, and reduced effector cell numbers after 7 days in culture than did native extracts. However, the frequency of
Foxp3+ Tregs in cultures were similar to those seen with native extract so that ratios of regulatory to effector T
cells were significantly increased in cultures stimulated with depigmented-polymerised extracts. Addition of 1α,
25-dihydroxyvitamin D3 further favoured Treg, and reduced effector cytokine production, but not interleukin-10.
Conclusions: Depigmented-polymerised allergen extracts appear to favour Treg expansion over activation of
effector T cells and this may relate to their demonstrated efficacy and safety in SIT. 1α, 25-dihydroxyvitamin D3
further reduces effector T cell activation by allergen extracts and may be a useful adjuvant for SIT.
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Specific allergen immunotherapy (SIT) is recommended
for persistent allergic rhinoconjunctivitis and asthma resist-
ant to pharmacotherapy, and is the only disease-modifying
treatment in that benefit persists after stopping treatment
[1,2]. However, subcutaneous injection of immunotherapy
(SCIT) extracts carries a risk of anaphylaxis, whilst sublin-
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unless otherwise stated.years. One approach to reducing the risk of anaphylaxis
with SCIT is to modify allergen extracts to reduce IgE
binding [3]. Such allergoids include extracts treated with
acid (“depigmented”), prior to polymerisation with glutaral-
dehyde [4]. These extracts showed efficacy in clinical trials
for both birch and grass pollen-related allergic rhinitis, and
house dust mite-related asthma [5-8]. In these studies and
large observational series, side effects were minimal [5-9].
The resulting depigmented-polymerised (Depig-pol) aller-
gen extracts are of very large molecular mass (0.5-3 MDa
as opposed to less than 100 KDa for native allergen ex-
tracts), and have at least 50 times reduced IgE binding
in vitro in competition assays and in vivo in skin prick
testing [4,10,11]. Analysis of sequences obtained by en-
zymatic digestion of Depig-pol and native extracts suggests. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Volunteer characteristics
Dermatophagoides pteronyssinus (HDM) Phleum pratense (Grass)
Donor ID IgE (kU/L) CAPclass SPT IgE (kU/L) CAPclass SPT
A03 3.85 3 4×4 9.83 3 10×6
A40 1.25 2 7×6 0.82 2 9×8
AR48 26 4 5×4 15.2 3 8×6
AR21 8.66 3 12×7 0.99 2 20×10
AR22 2.07 2 5×5 0.70 1 4×4
A58 6.75 3 6×5 1.31 2 5×4
Donor clinical characteristics are shown in brackets (AR = allergic rhinitis,
A = asthma), specific IgE concentration and CAP class for each allergen,
and size of skin prick test weal in mm.
Note equal proportions of male and female subjects were studied. Mean
(range) of allergic patients was 38 years old (25 - 63 years); mean age of nonatopic
individuals was 40 years old (30 - 47 years).
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mite and pollen extracts [10,11], and in vivo immunogen-
icity studies show induction of IgG directed against the ma-
jority of major allergens upon treatment of patients with
these extracts and in studies involving immunization of ex-
perimental animals [5-7,11].
Whilst allergoids have reduced IgE binding (allergen-
icity) which may improve safety, it has also been sug-
gested that they have reduced T cell stimulating activity
(immunogenicity) which could compromise efficacy [12].
Studies of T cell activity of allergoids in terms of prolif-
eration of primary T cells, lines or clones, have suggested
variable degrees of loss of ability to stimulate T cells, ei-
ther generally or restricted to some epitopes [12-16].
However, the immunological efficacy of SIT most likely
relates to induction of tolerance to allergens through in-
teractions with regulatory T cells (Treg) [17]. Studies
with unmodified allergen extracts suggest increased num-
bers and activity of both CD4+CD25hiFoxp3hi T cells and
IL-10 producing T cells after SIT treatment, together with
induction of the IL-10-dependent antibody IgG4 [17].
Thus expansion of Tregs may be a more relevant activity
to assess for allergen extracts for SIT.
In order to improve efficacy, reduce dosing and im-
prove safety of allergen immunotherapy a number of ad-
juvants have been examined. In particular, there is much
current interest in 1α, 25-dihydroxyvitamin D3, which
can expand both induced IL-10-producing and Foxp3+
Treg in vitro, and improved effects of immunotherapy in
animal models [18-21]. Vitamin D status and/or treat-
ment of human volunteers with vitamin D derivatives
correlated with or increased Foxp3+ T cell frequency in
the periphery [19] and the airway in asthmatics [20] and
IL-10 producing Treg in the periphery [18].
Here we have examined the relative stimulation of ef-
fector and regulatory T cells in vitro by unmodified and
depigmented-polymerised allergen extracts, together with
the effects of 1α, 25-dihydroxyvitamin D3.
Results
Depigmented-polymerised allergen extracts stimulate less
T cell proliferation than native extracts, but similar
cytokine production
Production of depigmented-polymerised extracts involves
two steps which might alter T cell reactivity (depigmen-
tation: acid hydrolysis then dialysis to remove low molecu-
lar weight non-allergen material, then polymerisation
with glutaraldehyde). Therefore initial timecourse and
dose-response experiments were performed to assess pro-
liferation of PBMC from atopic donors (Table 1) in cultures
stimulated with native, depigmented and depigmented-
polymerised (Depig-pol) house dust mite (HDM) and grass
pollen (GRASS) extracts. Maximal proliferation was seen at
day 7 for all extracts except for Depig-pol HDM extractwhich was highest at day 9 (Figure 1A). Note that PBMC
viability was comparable between HDM native and Depig-
pol stimulated cultures, 76.8% (+/- 23%) and 78.2% (+/-
26%), respectively. Data for some of the experiments with
grass pollen extracts has been presented elsewhere [7].
Proliferation for depigmented HDM and GRASS ex-
tracts was very similar to that seen for native extracts,
but proliferation was signficantly less for Depig-pol ex-
tracts of both HDM and GRASS when compared to na-
tive unmodified extracts (Figure 1B and ref [7]). For this
reason, further comparisons were between native and
Depig-pol extracts.
Cytokine production was also maximal at day seven for
all cytokines except IL-10 which peaked at day 5 (data not
shown). Seven days of culture was therefore used for fur-
ther comparisons (except for IL-10). Production of IL-5,
IL-10 and IL-13 did not differ significantly between cul-
tures stimulated with native or depigmented-polymerised
extracts of either HDM or GRASS (Figure 2, ref [7] and
data not shown), whilst there was a non-significant trend
for reduced IFNγ and significantly reduced IL-17 in
depig-pol-stimulated cultures compared to native extract.
Depigmented-polymerised allergen extracts expand
regulatory T cells more than effector T cells in culture
To examine effects of native and depigmented-polymerised
extracts in stimulation of regulatory or effector cells
we examined expression of CD25, Foxp3 and CD127
after 7 days of culture of PBMC. Gating strategy was
as described, to identify cells that we have previously
shown to be regulatory in cultures [19]. For both
HDM and GRASS, Depig-pol extracts expanded simi-
lar numbers of CD4+CD25+Foxp3hiCD127lo (regulatory
T cells) compared to native extracts, but reduced numbers
of CD4+CD25+Foxp3loCD127+ (effector cells, Figure 3A).
When expressed as a ratio of CD25+Foxp3hi CD127lo to
CD25+Foxp3loCD127+ cells this was significantly higher
for Depig-pol extracts of both HDM and GRASS when
Figure 1 Depigmented-polymerised house dust mite extract stimulates significantly less PBMC proliferation than unmodified native
extract. PBMC (2x106/mL) were cultured with depigmented-polymerised (Depig-pol), depigmented (Depig) or native HDM extracts at different
concentrations for different times: proliferation was assessed by thymidine incorporation, as described in Methods. N = 6. Statistical analysis by
ANOVA. A Time course for proliferation of Depig-pol, Depig and native HDM extract-stimulated PBMC at a concentration of 100 μg/mL of each
extract. p value for Depig-pol vs. native extract. B Dose-response for proliferation of Depig-pol, and native HDM extract-stimulated PBMC at day 7.
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(Figure 3B).
Addition of 1α, 25-dihydroxyvitamin D3 to cultures further
favours CD25hiFoxp3hiCD127lo T cells
Addition of 1α, 25-dihydroxyvitamin D3 at 10-7 M further
reduced expansion of effector cells in cultures stimulated
with both native and Depig-pol extracts of HDM and
GRASS (Figure 4A), whilst numbers of CD4+CD25+Fox-
p3hiCD127lo regulatory cells were not reduced. Thus the
ratio of regulatory to effector cells after cultures was fur-
ther increased by addition of 1α, 25-dihydroxyvitamin D3
(Figure 4B). In addition 1α, 25-dihydroxyvitamin D3 re-
duced effector cytokines, particularly IL-17 and IFNγ, but
did not significantly affect IL-10 production (Figure 5 and
data not shown).
Discussion
These data suggest reduced proliferation and cytokine
production (particularly IL-17 and IFNγ) by PBMC from
atopic donors stimulated with Depig-pol extracts com-
pared to native, unmodified allergen extracts for grasspollen and house dust mite. However, Depig-pol allergen
extracts for grass pollen and HDM favoured expansion
of regulatory T cells over effector T cells in vitro, and
this balance was further tilted towards regulation by 1α,
25-dihydroxyvitamin D3. Thus Depig-pol allergen ex-
tracts may favour regulatory T cells over effector T cell
activation, which might be expected to augment toler-
ance induction in SIT.
Several reports have previously examined T cell re-
sponses to allergoids [12-16]. All showed reduced prolifer-
ation of PBMCs stimulated with allergoid when compared
to native allergen, and variable reductions in cytokine pro-
duction. This difference in T cell proliferation between
allergoid and native extract was suggested to vary with
antigen presenting cell type, although this was not con-
firmed in a subsequent study [15,16]. Analysis of re-
sponses of T cell lines and clones suggested variable loss
of T cell epitopes in allergoid extracts compared to native
extracts [13-15]. Our data also suggests reduced prolifera-
tion and effector cytokine production by PBMC stimu-
lated by Depig-pol extracts compared with native extract,
and these findings were confirmed by reduced expansion
Figure 2 Depigmented-polymerised house dust mite extract stimulates significantly reduced IL-17 production than unmodified native
extract. PBMC (2×106/mL) were cultured with depigmented-polymerised (Depig-pol), depigmented (Depig) or native HDM extracts at different
concentrations for different times: cytokine production was assessed by CBA, as described in Methods. N = 6. Statistical analysis by ANOVA.
Dose-response for IL-10, IL-5, IFNγ and IL-17 production by Depig-pol, and native HDM extract-stimulated PBMC at day 5 (IL-10) or day 7 (IL-5,
IFNγ and IL-17).
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cultures. We would argue that reduced activation and ex-
pansion of effector T cells by Depig-pol extracts will actu-
ally be beneficial in the context of SIT, where effector T
cell activation may contribute to side effects. This is dem-
onstrated most graphically for peptide therapy where
small allergen peptides which did not cross link IgE none-
theless activated effector T cells and lead to isolated late
asthmatic reactions in patients [22]. We did not examine
loss of T cell epitopes comparing Depig-pol extracts with
native extracts, although previous mass spectroscopic ana-
lysis has suggested preservation of most major allergen se-
quences [10]. Even if some T cell epitopes were lost during
the depigmentation and polymerisation process, we would
argue that the critical activity for tolerance induction is
expansion of regulatory T cells that work in both antigen-
specific and non-antigen specific fashion, as shown by
linked suppression to cat major allergen Fel d 1 peptides
not included in the experimental peptide immunotherapy
treatment in an animal model [23].
Although Depig-pol extracts stimulated reduced ef-
fector T cell expansion and activation compared to na-
tive extracts, numbers of regulatory T cells were similar,
so the ratio of regulatory to effector T cells in cultures
stimulated with Depig-pol extracts was significantly higher
than for native extract. Activation requirements for effectorversus regulatory T cells are incompletely understood, but
we would suggest that antigen-presenting cell processing
of and activation by these molecules of vastly different
mass may be relevant in the case of Depig-pol versus na-
tive extracts [10,11].
Interestingly, our data both here and in previous stud-
ies [20] suggest that depigmented-polymerised extracts
and 1α, 25-dihydroxyvitamin D3 both favour Foxp3hi T
cells (by reducing expansion of effector T cells). Initial re-
ports suggested that 1α, 25-dihydroxyvitamin D3 acted to
expand IL-10 producing T cells [18]. However, our recent
data shows that 1α, 25-dihydroxyvitamin D3 can also ex-
pand Foxp3hi Tregs [20]. The type of Treg emerging
depended on the concentration of 1α, 25-dihydroxyvitamin
D3 in cultures, and the cytokine milieu and essentially no
co-expression of Foxp3 and IL-10 was observed, although
both populations exhibited comparable suppressive activity
[19,20]. The present findings are in keeping with that data
in that a relatively higher concentration favoured Foxp3hi
Tregs (albeit 10-7 M here rather than 10-6 M in an anti-
CD3 driven culture system), and in these conditions IL-10
producing T cells were not detected (data not shown).
Our previous report suggested that the major effect of
1α, 25-dihydroxyvitamin D3 was to suppress prolifera-
tion of effector T cells and maintain Foxp3 expression
by regulatory T cells: our current data agrees with this,
Figure 3 Depigmented-polymerised allergen extracts favour regulatory T cell-phenotype over effector phenotype. A Contour plots
showing CD4+CD25+Foxp3hi populations (regulatory phenotype) and CD4+CD25+Foxp3low cells (effector phenotype) after 7-day culture with
depigmented-polymerised (Depig-pol) or native HDM extracts. B Ratios of CD4+CD25+Foxp3hi to CD4+CD25+Foxp3low T cells from 7-day cultures
stimulated with depigmented-polymerised or native extracts. N = 5, p values for paired t-test.
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a preserved Foxp3hi Treg population [20].
SIT with depigmented-polymerised extracts, which have
at least 95% reduced IgE binding compared to native aller-
gen extract, has been shown to be clinically effective in re-
ducing symptom scores for rhinoconjunctivitis and asthma
with minimal side effects and rapid up-dosing [5-8]. Fur-
ther studies are required to examine the effects of Depig-
pol extracts on Tregs in vivo, and to determine whether
1α, 25-dihydroxyvitamin D3 can enhance tolerance in a
clinical setting of SIT.
Conclusion
Depigmented-polymerised allergen extracts appear to
favour Treg expansion over activation of effector T cells
to a greater extent than unmodified allergen extracts. 1α,25-dihydroxyvitamin D3 further reduces effector T cell
activation by both allergen extracts, and may be a useful
adjuvant for SIT.
Methods
Volunteers and peripheral blood mononuclear cell (PBMC)
culture
Atopic allergic volunteers were sensitized to both grass
pollen and house dust mite (by skin prick tests and/or
specific IgE). Clinical details are shown in Table 1. All
had persistent AR and in 3 cases asthma. None was
treated with systemic corticosteroids and all had stable
disease controlled with topical treatment only. None of
the volunteers had received immunotherapy. The study
was approved by Guy’s Hospital Ethics Committee and
all volunteers gave written consent. Skin prick tests were
Figure 4 1α, 25-dihydroxyvitamin D3 increases the ratio of regulatory to effector T cell phenotype. A Contour plots showing CD4+CD25
+FoxP3hi populations and CD4+CD25+Foxp3low T cells after 7 days culture with depigmented-polymerised (Depig-pol) or native grass pollen extracts
with and without 1α, 25-dihydroxyvitamin D3 (10-7 M). B Ratios of Foxp3hi to Foxp3low T cells in cultures stimulated for 7 days with HDM or grass
pollen with and without 1α, 25-dihydroxyvitamin D3. N = 5, analysis by paired t-test.
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and specific IgE was measured using immunoCAP (Phadia,
Uppsala, Sweden). PBMC were separated by Lymphoprep
density centrifugation (Axis-Shield, Oslo, Norway), then
cultured in RPMI 1640 media with L-glutamine, gentami-
cin (all from Invitrogen, Paisley, UK), and 5% AB human
serum (PAA, Pasching, Austria) in triplicate in 96 well
plates at 2×106 cells/ml for 7 days with a range of concen-
trations of allergen extracts or medium alone in a 5%CO2
incubator at 37°C. Proliferation was assessed by incorpor-
ation of titrated thymidine (1 μCi; added 16 hours before
analysis) and cytokine production by cytometric bead array
(BD Biosciences, Oxford UK). Depigmented-polymerised
Phleum pratense (Timothy grass) pollen and Dermatopha-
goides pteronyssinus (house dust mite, HDM) extracts were
compared with native, unmodified allergen extracts, and
initially with depigmented non-polymerised extracts (all
prepared as described by Laboratorios Leti, Tres Cantos,
Spain, 4).Assessment of regulatory and effector cells in culture
and effect of 1α, 25 hydroxyvitamin D3 Flow cytometry
was used to examine the relative numbers of T cells with
regulatory or effector phenotype after 7 days culture as
previously described [19] (CD4+CD25hiCD127loFoxp3hi
for regulatory T cells, and CD4+CD127+CD25+Foxp3lo
for effector T cells). All antibodies were from BD Biosci-
ences (Oxford, UK) except that for Foxp3, which was
from EBiosciences (Hatfield, UK). We have previously
used this gating strategy to identify regulatory T cells
after culture, and confirmed suppressive activity of these
cells by re-culture of sorted cells [19]. We added 1α, 25-
dihydroxyvitamin D3 (BIOMOL Research Labs, Plymouth
Meeting PA, USA) to further cultures of PBMC from
atopic donors with both depigmented-polymerised and
native allergen extracts. Pilot experiments showed the op-
timal dose of 1α, 25-dihydroxyvitamin D3 for expansion
of Foxp3+ T cells to be 10-7 M in this culture system (data
not shown).
Figure 5 1α, 25-dihydroxyvitamin D3 decreases production of effector cytokines but does not alter IL-10 production. Cytokine
production (by CBA) in 7-day PBMC cultures stimulated with (A) HDM or (B) Grass depigmented-polymerized (Depig-pol) or native extracts with
and without 1α, 25-dihydroxyvitamin D3 (10-7 M). N = 5, analysis by paired t-test or Wilcoxon test.
Urry et al. BMC Immunology 2014, 15:21 Page 7 of 8
http://www.biomedcentral.com/1471-2172/15/21
Urry et al. BMC Immunology 2014, 15:21 Page 8 of 8
http://www.biomedcentral.com/1471-2172/15/21Statistical analysis
Data for proliferation and cytokine production was com-
pared by ANOVA for dose response data for native and
Depig-pol extracts. Values for regulatory/effector cell ratios
and cytokines were compared by paired or unpaired t-test
or Mann Whitney U/Wilcoxon tests as appropriate after
testing for normality of distribution. All statistics were per-
formed using GraphPad Prism (La Jolla, CA, USA).
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